REVEAL-GENOMICS-S.L.
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509117263/en/
The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.
If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.
In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint. HER2DX® pCR-score and HER2DX® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.
The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."
Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.
REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."
HER2DX® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine
The inclusion of HER2DX® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.
This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.
About HER2DX®️
HER2DX®️ is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS®️ since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
HER2DX®️ is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.
HER2DX®️ predicts:
- Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
- pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
- ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.
About ECOG-ACRIN
ECOG-ACRIN is renowned for advancing precision medicine and biomarker research through its leadership of major clinical trials that integrate cutting-edge genomic approaches. Through the CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial Program, ECOG-ACRIN is collaborating with the Alliance for Clinical Trials in Oncology to investigate the optimization of therapy in patients with HER2+ breast cancer. The CompassHER2 pCR Trial (NCT04266249) was the first to open in this program, funded by the National Cancer Institute, part of the US National Institutes of Health.
Web: www.ecog-acrin.org, X: @eaonc. Other: Facebook, LinkedIn, and Instagram.
About REVEAL GENOMICS®️
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.
REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d’Hebron Institute of Oncology (VHIO).
REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.
Web: www.reveal-genomics.com. X: @revealgenomics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509117263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands the MasterFrame Series with the Compact and Modular MasterFrame 400 Mesh12.11.2025 13:07:00 CET | Press release
The New PC Case Combines Modular Flexibility with a Clean Design for Easy Builds and Polished Final Look Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the MasterFrame 400 Mesh, a compact PC case that brings the signature MasterFrame design language to a more accessible, desk-friendly format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112507322/en/ MasterFrame 400 Mesh shown with V4 3DHP air cooler. The MasterFrame 400 Mesh delivers FreeForm 2.0 modularity in a simplified build experience. It offers dual orientation for vertical or horizontal setups, repositionable brackets, and mesh-optimized airflow so builders can tailor layout and thermals with confidence. The result is a compact footprint that still supports serious hardware. The case is engineered for Micro-ATX and Mini-ITX systems and supports high-performance components without compromise. Builders can install GPU
IonQ to Highlight Real-World Quantum Applications at Web Summit 202512.11.2025 13:05:00 CET | Press release
IonQ’s Dr. Chris Ballance to speak on how fidelity breakthroughs are accelerating practical use cases and quantum advantage IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in Web Summit 2025, one of the largest technology events in Europe. IonQ’s President of Quantum Computing and co-founder of Oxford Ionics, Dr. Chris Ballance, is scheduled to speak during the conference’s AI Summit on Thursday, November 13, 2025, at 10:30 AM local time. The AI Summit session, “Quantum Without Compromise: The Race to Real-world Applications,” will be moderated by technology journalist, Mary-Ann Russon. The discussion will focus on IonQ’s recent breakthroughs in quantum gate fidelity and how these advancements underpin the company’s roadmap toward fault-tolerant systems. Dr. Ballance will also share how these engineering accomplishments translate into quantum computing’s growing impact across industries. “We’re at a pivotal moment where breakthroughs in quantum
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD12.11.2025 13:04:00 CET | Press release
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understanding (MOU) with Benta SAS. The MOU expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112416172/en/ PTSD is a chronic and debilitating condition that affects millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, there has been no new approved drug for PTSD in over two decades — underscoring a critical unmet medical need. As part of its clinical development pipeline, Ananda Scientific is currently advancing Nantheia
Global Airline Reliability Improves in October, Led by Asia-Pacific as North America Faces Operational Pressures; Cirium Analysis12.11.2025 13:00:00 CET | Press release
Cirium, the world’s most trusted source of aviation analytics, has published its October 2025 On-Time Performance (OTP) Report, covering more than 370,000 flights with 99.8% global coverage. The data indicates a 26% reduction in global cancellations compared with September, reflecting improved operational stability across the commercial aviation network. The results also highlight distinct regional dynamics shaping airline performance worldwide. Asia-Pacific carriers led the recovery, cutting flight cancellations by 43% as airlines across Japan, South Korea, and the Philippines strengthened network performance and capacity. Notably, the world’s top-performing airports in October — Harbin Taiping and Changchun Longjia in China, and Kaohsiung International in Taiwan — were all located in the region, underscoring its continued operational gains and steady recovery momentum. North American operations showed greater operational strain, with flight cancellations rising by about 12.6% month o
New Study Further Validates Environmental Benefits of Floor Refinishing Compared to Replacement12.11.2025 12:00:00 CET | Press release
Renovation of hard flooring surfaces, such as wood and resilient, saves up to 92 percent in CO2 emissions and up to 98 percent in energy usage A recent report and lifecycle assessment (LCA) conducted by IVL Swedish Environmental Research Institute confirms refinishing hard flooring surfaces, including wood, vinyl and linoleum, is more sustainable for the environment than replacing the flooring surfaces. This new study, which was conducted for the German market, is the next step of research inspired from a previous 2019 study conducted in Sweden. Both studies aim to evaluate the environmental impact of replacing a worn, damaged or outdated flooring surface compared to refinishing the flooring surface which may include sanding, finishing, staining, or painting. Bona, a global, family-owned company that supplies products for installing, renovating, maintaining, and restoring premium floors, commissioned this new study to build on the findings from a 2019 Swedish study. The new research fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom